Recursion Pharmaceuticals (RXRX) vs Spyre Therapeutics (SYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Spyre Therapeutics (SYRE) has outperformed Recursion Pharmaceuticals (RXRX) over the past year, gaining 304.8% versus a loss of 26.2%. Over five years, SYRE leads with a -58.1% price change compared with -77.1% for RXRX. Spyre Therapeutics is the larger company by market cap ($8.01 billion vs $2.34 billion), about 3.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RXRX | SYRE |
|---|---|---|
| Share price | $4.36 | $85.69 |
| Market cap | $2.34B | $8.01B |
| 1-day change | +10.38% | +7.25% |
| YTD return | +6.60% | +161.57% |
| 1-year return | -26.23% | +304.77% |
| 5-year return | -77.10% | -58.10% |
| EPS (TTM) | $-1.10 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $74.68M | $0 |
| Revenue growth (YoY) | +26.92% | — |
| Net income (latest FY) | $-644.76M | $-155.20M |
| Gross margin | 4.99% | — |
| Operating margin | -867.87% | — |
| Net margin | -863.35% | — |
| 52-week high | $7.18 | $110.18 |
| 52-week low | $2.77 | $18.12 |
| Distance from 52-week high | -39.28% | -22.22% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +65.60% | +40.28% |
| Average volume | 20.93M | 1.22M |
| Shares outstanding | 535.34M | 93.45M |
| Employees | 600 | 125 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Spyre Therapeutics is about 3.4 times larger than Recursion Pharmaceuticals by market value ($8.01B vs $2.34B).
- SYRE has outperformed RXRX by 331.0 percentage points over the past year.
About Recursion Pharmaceuticals
RXRX stock →Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 600 employees
About Spyre Therapeutics
SYRE stock →Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).
Health Care · Biotechnology: Pharmaceutical Preparations · 125 employees
RXRX vs SYRE FAQ
Which is bigger, Recursion Pharmaceuticals or Spyre Therapeutics?
Spyre Therapeutics (SYRE) is larger, with a market capitalization of $8.01B compared with $2.34B for Recursion Pharmaceuticals (RXRX).
Which stock has performed better over the past year, RXRX or SYRE?
SYRE returned +304.77% over the past 12 months, compared with -26.23% for RXRX (price return, excluding dividends). Past performance does not predict future results.
Are Recursion Pharmaceuticals and Spyre Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Recursion Pharmaceuticals and Biotechnology: Pharmaceutical Preparations for Spyre Therapeutics.